ORION CORPORATION STOCK EXCHANGE RELEASE 25 MARCH 2014 4.30 P.M.
Orion Corporation: Organising meeting of the Board of Directors
In its organising meeting, the Board of Directors of Orion Corporation, which
was elected today by the Annual General Meeting of the Shareholders, has
elected Jukka Ylppö as Vice Chairman.
The compositions of the Board committees were decided to be as follows:
Hannu Syrjänen, Chairman
Heikki Westerlund, Chairman
Sirpa Jalkanen, Chairman
The members to the Nomination Committee will be elected later.
The Board of Directors has assessed the independence of its members and
concluded that all the members are independent of the company and its
Timo Lappalainen Olli Huotari
President and CEO Senior VP, Corporate Functions
Orionintie 1A, FI-02200 Espoo, Finland
Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical ingredients
and diagnostic tests. The company is continuously developing new drugs and
treatment methods. Pharmaceutical R&D focuses on central nervous system drugs,
oncology and critical care drugs, and Easyhaler® pulmonary drugs.
Orion's net sales in 2013 amounted to EUR 1,007 million and the company had
about 3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.